Ischemia Reperfusion Injury Market Report 2025

The ischemia reperfusion injury market size has grown strongly in recent years. It will grow from $1.56 billion in 2024 to $1.68 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth observed during the historic period can be attributed to factors such as the increasing prevalence of cardiovascular diseases, a rise in surgical procedures, growing demand for organ transplantation, an expanding aging population, and a higher incidence of stroke.

The ischemia reperfusion injury market size is expected to see strong growth in the next few years. It will grow to $2.26 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. Looking ahead, the growth during the forecast period is expected to be driven by factors such as the increasing demand for biomarker-based diagnostics, greater awareness of organ preservation techniques, a rising incidence of myocardial infarction, higher investments in pharmaceutical research and development, and growing demand for stem cell therapies. Key trends anticipated in the forecast period include advancements in imaging technologies, the development of novel pharmacological agents, the integration of AI and machine learning in treatments, the adoption of 3D printing for organ modeling, and a shift toward telemedicine.

The increasing prevalence of cardiovascular diseases is expected to drive the growth of the ischemia-reperfusion injury market in the future. Cardiovascular diseases are a group of conditions that affect the heart and blood vessels, including coronary artery disease, heart failure, and stroke. The rise in these diseases is primarily attributed to unhealthy lifestyle habits and an aging population. Diets high in saturated fats, sugar, and salt, combined with insufficient physical activity, have contributed to rising rates of obesity, hypertension, and diabetes, which are major risk factors for cardiovascular conditions. Ischemia-reperfusion injury exacerbates cardiovascular diseases by intensifying tissue damage through oxidative stress, inflammation, and cell death, ultimately impairing heart function and raising the risk of heart failure and other complications. For example, the Australian Institute of Health and Welfare reported that deaths from coronary heart disease in Australia rose from 14,100 in 2021 to 14,900 in 2022. Thus, the increasing prevalence of cardiovascular diseases is contributing to the growth of the ischemia-reperfusion injury market.

The increasing frequency of organ transplants is expected to further boost the growth of the ischemia-reperfusion injury market. Organ transplantation involves the surgical transfer of a healthy organ from a donor to a recipient to replace a failing or damaged organ. The rise in organ transplants can be attributed to advances in medical technology and the growing number of organ failure patients. Improvements in surgical techniques, immunosuppressive drugs, and organ preservation methods have significantly enhanced the success rates of organ transplants. Ischemia-reperfusion injury (IRI) can be managed through advanced preservation techniques during transplantation, minimizing ischemia-induced damage and improving the function and survival of the transplanted organ. For instance, according to the United Network for Organ Sharing (UNOS), the United States saw 42,887 organ transplants in 2022, a 3.7% increase from 2021. As a result, the rise in organ transplants is playing a key role in the expansion of the ischemia-reperfusion injury market.

Companies in the ischemia-reperfusion injury market are focusing on developing innovative treatments, such as ketamine-based therapies, to prevent tissue damage and inflammation caused by ischemic events. Ketamine-based treatments use ketamine, a dissociative anesthetic, to address various health conditions, primarily in the treatment of mental health disorders such as depression, anxiety, and PTSD, as well as for pain management. For example, in December 2022, PharmaTher Holdings Ltd., a Canadian pharmaceutical company, received orphan drug designation from the U.S. Food and Drug Administration (FDA) for ketamine to prevent ischemia-reperfusion injury during organ transplantation. Ketamine reduces ischemia-reperfusion injury by inhibiting NF-κB, which suppresses the production of inflammatory cytokines such as IL-6 and TNF-α. Additionally, it exhibits anti-inflammatory properties by reducing leukocyte reactivity, helping minimize immune-mediated damage to transplanted organs.

Major players in the ischemia reperfusion injury market are Pfizer Inc., Prolong Pharmaceuticals LLC, BMG LABTECH GmbH, Domainex Ltd, CFM Pharma Holding BV, Simcere Innovation Inc., Larix Bioscience LLC, Faron Pharmaceuticals Oy, LUCA Science Inc., Faraday Pharmaceuticals Inc., Athersys Inc., Alloksys Life Sciences B.V., Ischemix Inc., New Horizons Pharma Inc., Oxitope Pharma BV, PharmaTher Holdings Ltd, Revive Therapeutics Ltd, Corline Biomedical AB, Angion Biomedica Corp., Radikal Therapeutics Inc.

North America was the largest region in the ischemia reperfusion injury market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in ischemia-reperfusion injury report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the ischemia-reperfusion injury market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Ischemia-reperfusion injury refers to tissue damage that occurs when blood flow is restored to tissues after a period of ischemia (lack of oxygen). The return of circulation can lead to inflammation and oxidative damage. This injury involves complex pathophysiological processes that have both local and systemic effects.

The primary treatment types for ischemia-reperfusion injury include pharmacological and non-pharmacological therapies. Pharmacological treatments involve the use of medications designed to prevent or address the underlying mechanisms, such as oxidative stress, inflammation, and cell death. These therapies are applied in various conditions, including cardiovascular diseases, stroke, organ transplantation, heart attack, and diabetes. The end users of these treatments include hospitals, clinics, ambulatory services, and nursing homes.

The ischemia reperfusion injury market research report is one of a series of new reports that provides ischemia reperfusion injury market statistics, including the ischemia reperfusion injury industry global market size, regional shares, competitors with the ischemia reperfusion injury market share, detailed ischemia reperfusion injury market segments, market trends, and opportunities, and any further data you may need to thrive in the ischemia reperfusion injury industry. This ischemia reperfusion injury market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The ischemia-reperfusion injury market consists of revenues earned by entities by providing services such as diagnostic imaging services, surgical interventions, pharmacological treatment services, rehabilitation and physical therapy, research, and clinical trial services. The market value includes the value of related goods sold by the service provider or included within the service offering. The ischemia-reperfusion injury market also includes sales of products including pharmaceuticals and therapeutics, medical devices, diagnostic tools and kits, reperfusion equipment, research tools, and reagents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.